Ashley Teusink-Cross
Overview
Explore the profile of Ashley Teusink-Cross including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
367
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Badia P, Andersen H, Haslam D, Nelson A, Pate A, Golkari S, et al.
Biol Blood Marrow Transplant
. 2020 Jun;
26(9):1704-1710.
PMID: 32505810
Bloodstream infections (BSIs) from oral organisms are a significant cause of morbidity and mortality in hematopoietic stem cell transplantation (HSCT) recipients. There are no proven strategies to decrease BSIs from...
22.
Gloude N, Dandoy C, Davies S, Myers K, Jordan M, Marsh R, et al.
J Clin Immunol
. 2020 May;
40(5):699-707.
PMID: 32447592
Hemophagocytic lymphohistiocytosis (HLH) is a syndrome of excessive immune system activation driven mainly by high levels of interferon gamma. The clinical presentation of HLH can have considerable overlap with other...
23.
Khandelwal P, Fukuda T, Teusink-Cross A, Kashuba A, Lane A, Mehta P, et al.
Bone Marrow Transplant
. 2020 Apr;
55(8):1552-1559.
PMID: 32273585
We report results of a phase II study of maraviroc to prevent acute graft versus host disease (GVHD) in children undergoing allogeneic hematopoietic stem cell transplant (HSCT). Oral maraviroc was...
24.
Teusink-Cross A, Davies S, Grimley M, Chandra S, Flannery A, Dandoy C, et al.
Pediatr Transplant
. 2020 Mar;
24(3):e13692.
PMID: 32202691
cGVHD is a significant cause of morbidity and mortality after transplant. Ibrutinib has been studied as treatment for cGVHD in the adult population. Pediatric dosing and safety of ibrutinib are...
25.
Jodele S, Dandoy C, Lane A, Laskin B, Teusink-Cross A, Myers K, et al.
Blood
. 2020 Jan;
135(13):1049-1057.
PMID: 31932840
Overactivated complement is a high-risk feature in hematopoietic stem cell transplant (HSCT) recipients with transplant-associated thrombotic microangiopathy (TA-TMA), and untreated patients have dismal outcomes. We present our experience with 64...
26.
Mehta P, Emoto C, Fukuda T, Seyboth B, Teusink-Cross A, Davies S, et al.
Biol Blood Marrow Transplant
. 2019 Jul;
25(12):2416-2421.
PMID: 31326610
It is well known that pharmacokinetics (PK)-guided busulfan (BU) dosing increases engraftment rates and lowers hepatotoxicity in patients undergoing hematopoietic cell transplantation (HCT). However, there are no published PK data...
27.
Wallace G, Jodele S, Myers K, Dandoy C, El-Bietar J, Nelson A, et al.
Biol Blood Marrow Transplant
. 2018 May;
24(9):1856-1860.
PMID: 29782992
Vitamin D deficiency is prevalent among childhood hematopoietic stem cell transplantation (HSCT) recipients and associated with inferior survival at 100 days after transplantation. Achieving and maintaining therapeutic vitamin D levels...
28.
Jodele S, Dandoy C, Myers K, Wallace G, Lane A, Teusink-Cross A, et al.
Bone Marrow Transplant
. 2018 Apr;
53(10):1311-1318.
PMID: 29674658
Transplant-associated thrombotic microangiopathy (TA-TMA) is an increasingly recognized complication of hematopoietic cell transplant that can result in multi-organ failure (MOF). Patients undergoing high-dose chemotherapy with autologous stem cell transplant (aHCT)...
29.
Chandra S, Fukuda T, Mizuno K, Davies S, Teusink-Cross A, Tarin R, et al.
J Antimicrob Chemother
. 2018 Feb;
73(6):1651-1658.
PMID: 29481593
Background: Micafungin has a distinct advantage for antifungal prophylaxis in HSCT owing to its better safety profile, specifically in terms of hepatic and renal toxicity. In children, prophylactic micafungin is...
30.
Wallace G, Myers K, Teusink-Cross A, Davies S, Khandelwal P, Jodele S
Bone Marrow Transplant
. 2018 Jan;
53(5):628-633.
PMID: 29335622
No abstract available.